

## Publications

The Influence of Socioeconomic Factors on Access to Biologics in Psoriasis

Norlin JM, Löfvendahl S, Schmitt-Egenolf M

J. Clin. Med. 2023, 12(23), 7234; doi: 10.3390/jcm12237234

<https://pubmed.ncbi.nlm.nih.gov/38068286/>

The Disruptive Force of Real-World Evidence

Schmitt-Egenolf M

J Clin Med. 2023 Jun 13;12(12):4026. doi: 10.3390/jcm12124026

<https://pubmed.ncbi.nlm.nih.gov/37373719/>

Experience-based health state valuation using the EQ VAS:

a register-based study of the EQ-5D-3L among nine patient groups in Sweden

Teni FS, Burström K, Devlin N, Parkin D, Rolfson O; Swedish Quality Register (SWEQR) Study Group.

Health Qual Life Outcomes. 2023 Apr 10;21(1):34. doi: 10.1186/s12955-023-02115-z

<https://pubmed.ncbi.nlm.nih.gov/37038172/>

The Use of IL-17 and IL-23 Inhibitors in Swedish Clinical Practice:

A Register-Based Analysis.

Norlin JM, Löfvendahl S, Schmitt-Egenolf M

Dermatology. 2023;239(2):262-266. doi: 10.1159/000528007

<https://pubmed.ncbi.nlm.nih.gov/36516805/>

Severity of psoriasis: time to disentangle severity from symptom control.

Geale K, Schmitt-Egenolf M

Br J Dermatol. 2022 Jun;186(6):1033-1034. doi: 10.1111/bjd.21023

<https://pubmed.ncbi.nlm.nih.gov/35048366/>

Longitudinal study of patients' health-related quality of life using EQ-5D-3L in 11 Swedish National Quality Registers.

Teni FS, Rolfson O, Devlin N, Parkin D, Naucmér E, Burström K; Swedish Quality Register (SWEQR) Study Group.

BMJ Open. 2022 Jan 6;12(1):e048176. doi: 10.1136/bmjopen-2020-048176

<https://pubmed.ncbi.nlm.nih.gov/34992101/>

Impact of Bariatric Surgery on Moderate to Severe Psoriasis:

A Retrospective Nationwide Registry Study

Laskowski M, Schiöler L, Ottosson J, Schmitt-Egenolf M, Wennberg AM, Olbers T, Torén K, Gustafsson H.

JMIR Res Protoc 2021 Aug 27;10(8):e27669

<https://pubmed.ncbi.nlm.nih.gov/33954800/>

Variations in Patients' Overall Assessment of Their Health Across and Within Disease Groups Using the EQ-5D Questionnaire: Protocol for a Longitudinal Study in the Swedish National Quality Registers.

Teni FS, Rolfson O, Devlin N, Parkin D, Nauc ler E, Burstr m K; Swedish Quality Register (SWEQR) Study Group.

JMIR Res Protoc. 2021 Aug 27;10(8):e27669. doi: 10.2196/27669

<https://pubmed.ncbi.nlm.nih.gov/34448726/>

Complete skin clearance and beyond

Schmitt-Egenolf M

Br J Dermatol. 2021 Jan;184(1):3-4. doi: 10.1111/bjd.19544

<https://pubmed.ncbi.nlm.nih.gov/33029797/>

Association of Skin Psoriasis and Somatic Comorbidity with the Development of Psychiatric Illness in a Nationwide Swedish Study.

Geale K, Henriksson M, Jokinen J, Schmitt-Egenolf M.

JAMA Dermatol. 2020 Jul 1;156(7):795-804. doi: 10.1001/jamadermatol.2020.1398

[www.ncbi.nlm.nih.gov/pubmed/32492085](http://www.ncbi.nlm.nih.gov/pubmed/32492085)

Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.

Norlin JM, Nilsson K, Persson U, Schmitt-Egenolf M.

Br J Dermatol. 2020 Apr;182(4):965-973. doi: 10.1111/bjd.18361

[www.ncbi.nlm.nih.gov/pubmed/31325318](http://www.ncbi.nlm.nih.gov/pubmed/31325318)

Methotrexate Management in Psoriasis: Are We Following the Guidelines?

Lindqvist T, Salah LA, Gillstedt M, Wennberg AM, Osmancevic A.

Acta Derm Venereol. 2018 Apr 16;98(4):449-451

[www.ncbi.nlm.nih.gov/pubmed/29199349](http://www.ncbi.nlm.nih.gov/pubmed/29199349)

Patient Registries for Safety

Schmitt-Egenolf M. In: Evidence Based Pharmacovigilance:

Clinical and Quantitative Aspects. Ed.: Andrew Bate.

Springer Verlag, Berlin 2018. ISBN: 978-1-4939-8816-7

[www.springer.com/us/book/9781493988167](http://www.springer.com/us/book/9781493988167)

Sustained PASI, DLQI and EQ-5D response of biologic treatment in psoriasis:

10 years of real-world data in the Swedish National Psoriasis Register

F Hjalte, K Steen Carlsson, M Schmitt-Egenolf

Br J Dermatol. 2018 Jan;178(1):245-252

[www.ncbi.nlm.nih.gov/pubmed/28644904](http://www.ncbi.nlm.nih.gov/pubmed/28644904)

(The future of psoriasis care - essential for the future of dermatology)

Psoriasisvårdens framtid – väsentligt för dermatologins framtid

Katarina Lundqvist, Marcus Schmitt-Egenolf

D&V (Swedish Society for Dermatology & Venereology) Nr 9 · 1/2017

[www.ssdv.se/pdf/1709\\_DoV\\_low.pdf](http://www.ssdv.se/pdf/1709_DoV_low.pdf)

Severity of psoriasis differs between men and women - a registry based study of the clinical outcome measure Psoriasis Area and Severity Index (PASI) in 4045 patients

D Hägg, M Eriksson, A Sundström, M Schmitt-Egenolf

Am J Clin Dermatol. 2017 Aug;18(4):583-590

[www.ncbi.nlm.nih.gov/pubmed/28342016](http://www.ncbi.nlm.nih.gov/pubmed/28342016)

Real-world outcomes in 2,646 psoriasis patients:

One in five has PASI  $\geq$  10 and/or DLQI  $\geq$  10 under ongoing systemic therapy

J M Norlin, U Persson, M Schmitt-Egenolf

J Dermatolog Treat. 2017 Sep;28(6):500-504

[www.ncbi.nlm.nih.gov/pubmed/28132580](http://www.ncbi.nlm.nih.gov/pubmed/28132580)

Regional differences in the prescription of biologics for psoriasis in Sweden:  
a register-based study of 4,168 patients

P S Calara, R Althin, K Steen Carlsson, M Schmitt-Egenolf

BioDrugs. 2017 Feb;31(1):75-82

[www.ncbi.nlm.nih.gov/pubmed/28097638](http://www.ncbi.nlm.nih.gov/pubmed/28097638)

A Retrospective Study of Patients with Psoriasis Treated with Biologics: Relation to Body Mass Index and Gender.

Salah LA, Gillstedt M, Osmanovic A

Acta Derm Venereol. 2016 Nov 2;96(7):974-975

[www.ncbi.nlm.nih.gov/pubmed/27120180](http://www.ncbi.nlm.nih.gov/pubmed/27120180)

Healthcare provider and switch to biologics in psoriasis:

evidence from real world practice

P S Calara, J M Norlin, R Althin, K Steen Carlsson, U Persson,

M Schmitt-Egenolf

BioDrugs. 2016 Apr;30(2): 145-51

[www.ncbi.nlm.nih.gov/pubmed/26883786](http://www.ncbi.nlm.nih.gov/pubmed/26883786)

Evaluating equality in psoriasis healthcare:

a cohort study of the impact of age on prescription of biologics

K Geale M, Henriksson, M Schmitt-Egenolf

The British journal of dermatology 2016 Mar;174(3): 579-87

[www.ncbi.nlm.nih.gov/pubmed/26616003](http://www.ncbi.nlm.nih.gov/pubmed/26616003)

Psoriasis in Sweden: observational studies from an epidemiological perspective

PhD Thesis of David Hägg, Umeå university, Sweden 2016

<https://www.dissertations.se/dissertation/4ba113bee8/>

<http://umu.diva-portal.org/smash/get/diva2:891012/FULLTEXT01.pdf>

Register-Based Evaluation of Relative Effectiveness of New Therapies:  
Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.

J M Norlin, K Steen Carlsson, U Persson, M Schmitt-Egenolf

BioDrugs. 2015 Dec; 29(6): 389-98

[www.ncbi.nlm.nih.gov/pubmed/26670179](http://www.ncbi.nlm.nih.gov/pubmed/26670179)

(How to measure the severity of psoriasis?) Hur kan man mäta psoriasis svårighetsgrad?

M Schmitt-Egenolf

Reuma Bulletin Vetenskap (svensk reumatologisk förening) 103 2/2015 27-28 (2015)

<https://etidning.svenskreumatologi.se/p/rb-vetenskap/2015-04-15/r/1/1/6013/1010379>

Real-World Outcome Analysis of Continuously and Intermittently Treated Patients with  
Moderate to Severe Psoriasis after Switching to a Biologic Agent

Hjalte F, Steen Carlsson K, M Schmitt-Egenolf

Dermatology. 2015; 230 (4): 347-53

[www.ncbi.nlm.nih.gov/pubmed/25721571](http://www.ncbi.nlm.nih.gov/pubmed/25721571)

Decision for biological treatment in real life is more strongly associated with the Psoriasis  
Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI)

D Hägg, M Eriksson, A Sundström, M Schmitt-Egenolf

J Eur Acad Dermatol Venereol. 2015 Mar; 29(3): 452-6

[www.ncbi.nlm.nih.gov/pubmed/24911993](http://www.ncbi.nlm.nih.gov/pubmed/24911993)

Resource use in patients with psoriasis after the introduction of biologics in Sweden - Direct  
costs increase, whereas indirect costs decrease

J M Norlin, K Steen Carlsson, U Persson, M Schmitt-Egenolf

Acta Derm Venereol. 2015 Feb;95(2):156-61

[www.ncbi.nlm.nih.gov/pubmed/24819980](http://www.ncbi.nlm.nih.gov/pubmed/24819980)

(Register studies measure the effectiveness of drugs in clinical practice) Kvalitetsregister för  
att mäta effektivitet av läkemedel i klinisk praxis –  
exempel ifrån PsoReg

J M Norlin, M Schmitt-Egenolf, K Steen Carlsson, U Persson,

Läkartidningen 2014 24:2014 p. 1061-63

[www.ncbi.nlm.nih.gov/pubmed/25129915](http://www.ncbi.nlm.nih.gov/pubmed/25129915)

The higher proportion of men with psoriasis treated with biologics may be explained by  
more severe disease in men

D Hägg, M Eriksson, A Sundström, M Schmitt-Egenolf

PLoS One. 2013 May 15;8(5):e63619

[www.ncbi.nlm.nih.gov/pubmed/23691076](http://www.ncbi.nlm.nih.gov/pubmed/23691076)

Effectiveness and costs of new medical technologies: register-based research in psoriasis

PhD Thesis of Jenny Norlin, Umeå university, Sweden 2013

[www.dissertations.se/dissertation/6646d14e86/](http://www.dissertations.se/dissertation/6646d14e86/)

<http://umu.diva-portal.org/smash/get/diva2:658776/FULLTEXT01.pdf>

Switch to Biologic Agent in Psoriasis Significantly Improved Clinical and Patient Reported Outcomes in Real-World Practice

J M Norlin, K Steen Carlsson, U Persson, M Schmitt-Egenolf

Dermatology. 2012; 225(4):326-32

[www.ncbi.nlm.nih.gov/pubmed/23328678](http://www.ncbi.nlm.nih.gov/pubmed/23328678)

Gender and the treatment of immune-mediated chronic inflammatory diseases: Rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study.

Lesuis N, Befrits R, Nyberg F, van Vollenhoven RF

BMC Med. 2012 Aug 1;10:82.

[www.ncbi.nlm.nih.gov/pubmed/22853635](http://www.ncbi.nlm.nih.gov/pubmed/22853635)

Challenges for synthesising data in a network of registries for systemic psoriasis therapies

A D Ormerod, M Augustin, C Baker, O Chosidow, A D Cohen, T N Dam, I Garcia-Doval, L L

Lecluse, M Schmitt-Egenolf, P I Spuls, K D Watson, L Naldi

Dermatology. 2012;224(3):236-43

[www.ncbi.nlm.nih.gov/pubmed/22678413](http://www.ncbi.nlm.nih.gov/pubmed/22678413)

Analysis of Three Outcome Measures in Moderate to Severe Psoriasis - A Registry Based Study of 2.450 Patients

J M Norlin, K Steen Carlsson, U Persson, M Schmitt-Egenolf

The British journal of dermatology. 12/2011; 166(4):797-802

[www.ncbi.nlm.nih.gov/pubmed/22182212](http://www.ncbi.nlm.nih.gov/pubmed/22182212)

National Registries of Systemic Treatment for Psoriasis and the European 'Psonet' Initiative

Lecluse LLA, Naldi L, Stern R, Spuls PI, for the Psonet study network

Dermatology (Basel, Switzerland). 01/2009; 218(4):347-56

[www.ncbi.nlm.nih.gov/pubmed/19077384](http://www.ncbi.nlm.nih.gov/pubmed/19077384)

How Dermatologists Can Evaluate Systemic Psoriasis Treatments

M Schmitt-Egenolf

Forum for Nord Derm Ven 14 38-40 (2009)

[www.medicaljournals.se/forum/articles/14/2/38-40.pdf](http://www.medicaljournals.se/forum/articles/14/2/38-40.pdf)

PsoReg -- the Swedish registry for systemic psoriasis treatment. The registry's design and objectives

M Schmitt-Egenolf

Dermatology (Basel, Switzerland). 02/2007; 214(2):112-7.

[www.ncbi.nlm.nih.gov/pubmed/17341858](http://www.ncbi.nlm.nih.gov/pubmed/17341858)

Psoriasis therapy in real life: the need for registries

M Schmitt-Egenolf

Dermatology (Basel, Switzerland). 02/2006; 213(4):327-30

[www.ncbi.nlm.nih.gov/pubmed/17135739](http://www.ncbi.nlm.nih.gov/pubmed/17135739)

PsoReg - The Quality Register for Systemic Psoriasis Treatment  
M Schmitt-Egenolf  
Forum for Nord Derm Ven 9 104-107 (2004)  
[www.medicaljournals.se/forum/articles/9/4/94-97.pdf](http://www.medicaljournals.se/forum/articles/9/4/94-97.pdf)